Annovis Bio Promotes Cheng Fang to Chief Scientific Officer Amid Key Phase 3 Alzheimer's Trial

Annovis Bio (NYSE: ANVS) has announced the promotion of Cheng Fang, Ph.D., to chief scientific officer, effective immediately. Fang, who joined the company in 2021 and most recently served as senior vice president of research and development, will oversee scientific strategy and research operations across Annovis’ Alzheimer’s disease and Parkinson’s disease programs, including translational science, clinical development, biomarker strategy and regulatory interactions.

The promotion comes at a critical time for Annovis as it advances its lead drug candidate, buntanetap, toward top-line data from its pivotal Phase 3 Alzheimer’s disease study and a subsequent New Drug Application (NDA) submission. According to the company, Fang has played a key role in advancing its clinical development efforts and will lead the scientific strategy through upcoming clinical and regulatory milestones. The full press release is available at https://ibn.fm/c9jdt.

Fang’s promotion underscores Annovis’ commitment to its pipeline of neurodegenerative disease therapies. Buntanetap, an investigational once-daily oral therapy, works by inhibiting the translation of multiple neurotoxic proteins, including APP, amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients with Alzheimer’s and Parkinson’s diseases.

Annovis is a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania. The company focuses on developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). For more information, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X.

The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.